Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | THOR-707 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
THOR-707 | THOR707|THOR 707|SAR444245|SAR-444245|SAR 444245 | THOR-707 is a pegylated recombinant version of IL-2 that binds IL2beta, but does not bind to IL-2 alpha, potentially resulting in activation and tumor infiltration of CD8-positive T cells without proliferation of CD4-positive immune cells (Annals of Oncology (2019) 30 (suppl_5): v475-v532). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04009681 | Phase Ib/II | THOR-707 + unspecified PD-L1 antibody THOR-707 + unspecified PD-1 antibody THOR-707 THOR-707 + unspecified CTLA4 antibody | A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | Recruiting | USA | ESP | AUS | 3 |